Clinical trial
Efficacy of Quetiapine in Generalised Social Anxiety Disorder
NCT00302770 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00302770 |
|---|---|
| Title | Efficacy of Quetiapine in Generalised Social Anxiety Disorder |
| Official title | Efficacy of Quetiapine in Generalised Social Anxiety Disorder, a Double-blind, Placebo-controlled Study |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Social Anxiety Disorder |
| Intervention type | Drug |
| Interventions | quetiapine |
| Enrollment | 50 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Mar 15, 2006 |
| Last update posted | Jan 27, 2011 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: